NasdaqGM - Nasdaq Real Time Price USD

Aquestive Therapeutics, Inc. (AQST)

3.4100

+0.2300

+(7.23%)

At close: 4:00:01 PM EDT

3.5000

+0.09

+(2.64%)

After hours: 4:39:17 PM EDT

Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%

Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders have seen the share price descend 18% over the month. In...

Simply Wall St. 9 days ago

AQST
+7.23%
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article. Wall Street analysts believe AQST has a 245% upside potential over the next 12 months. Aquestive Therapeutics, Inc. (NASDAQ:AQST) Upside Potential: 245.96% Aquestive Therapeutics (NASDAQ:AQST) stands out as […]

Insider Monkey 14 days ago

AQST
+7.23%
Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ...

Despite a challenging quarter with decreased revenues and increased losses, Aquestive Therapeutics Inc (AQST) focuses on strategic preparations for the anticipated launch of Anaphylm in 2026.

GuruFocus.com 21 days ago

AQST
+7.23%
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 22 days ago

AQST
+7.23%
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -41.18% and 28.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 22 days ago

AQST
+7.23%
Aquestive Therapeutics: Q1 Earnings Snapshot

WARREN, N.J. (AP) — Aquestive Therapeutics Inc. AQST) on Monday reported a loss of $22.9 million in its first quarter. On a per-share basis, the Warren, New Jersey-based company said it had a loss of 24 cents.

Associated Press Finance 23 days ago

AQST
+7.23%
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patie

GlobeNewswire 23 days ago

AQST
+7.23%
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will als

GlobeNewswire 30 days ago

AQST
+7.23%
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025. Management will host a conference c

GlobeNewswire last month

AQST
+7.23%
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks last month

RXRX

AQST
+7.23%
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17. About Aquestive Therapeutics, Inc.Aq

GlobeNewswire last month

AQST
+7.23%
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today

GlobeNewswire 2 months ago

AQST
+7.23%
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts

Shareholders might have noticed that Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) filed its annual result this time...

Simply Wall St. 2 months ago

AQST
+7.23%
Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Aquestive Therapeutics Inc (AQST) progresses with FDA filings and international expansion plans, despite facing revenue declines and increased expenses.

GuruFocus.com 2 months ago

AQST
+7.23%
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 months ago

AQST
+7.23%
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -35.71% and 12.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AQST
+7.23%
Aquestive Therapeutics: Q4 Earnings Snapshot

The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share. The specialty pharmaceutical company posted revenue of $11.9 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $13.5 million.

Associated Press Finance 2 months ago

AQST
+7.23%
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment community conference ca

GlobeNewswire 2 months ago

AQST
+7.23%
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in March 2025 as follows: Leerink's Global Biopharma Conference 2025 to take place from March 10th to March 12th: fireside chat to t

GlobeNewswire 3 months ago

AQST
+7.23%
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2024 and provide an update on recent developments in its business after market close on Wednesday, March 5, 2025. Management will host a con

GlobeNewswire 3 months ago

AQST
+7.23%

Performance Overview

Return	AQST	S&P 500 (^GSPC)
YTD	-4.21%	+1.52%
1-Year	+15.59%	+12.84%
3-Year	+255.21%	+45.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aquestive Therapeutics, Inc. (AQST)

Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%

Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential

Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ...

Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Aquestive Therapeutics: Q1 Earnings Snapshot

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts

Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics: Q4 Earnings Snapshot

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Performance Overview